Skip to main content
Pharma Mar S.A. logo

Pharma Mar S.A. — Investor Relations & Filings

Ticker · PHM ISIN · ES0169501022 LEI · 959800QWKZ45ZQC2AV58 MC Manufacturing
Open in API
Filings indexed 351 across all filing types
Latest filing 2022-02-28 Annual Report
Country ES Spain
Listing MC PHM

About Pharma Mar S.A.

https://pharmamar.com/en/

Pharma Mar S.A. is a biopharmaceutical company specializing in the discovery, development, and commercialization of oncology treatments derived from marine sources. A pioneer in its field since 1986, the company leverages marine biodiversity to develop innovative therapies for cancer, with a particular focus on rare tumors. Its integrated R&D pipeline spans from the exploration of marine invertebrates to the marketing of approved drugs. The company maintains an extensive collection of over 500,000 marine samples, which serves as the foundation for its drug discovery programs. Key commercialized products include Yondelis® (trabectedin) for advanced soft tissue sarcoma and ovarian cancer, Zepzelca® (lurbinectedin) for small cell lung cancer, and Aplidin® (plitidepsin) for multiple myeloma.

Recent filings

Filing Released Lang Actions
Annual Report 2021
Annual Report Classification · 100% confidence The document contains detailed consolidated annual financial statements for the fiscal year ended December 31, 2021, including balance sheets, income statements, statements of changes in equity, and cash flow statements. The presence of comprehensive financial data, notes references, and the full fiscal year period indicates this is a full annual report. The document length is substantial (15,000 characters), and it is not merely an announcement or certification. Therefore, it fits the definition of an Annual Report (10-K). FY 2021
2022-02-28 Spanish
La Sociedad informa que organizará un seminario web con oncólogos líderes de opinión en cáncer de pulmón microcítico el 9 de marzo de 2022 a las 19.00 CET
Regulatory Filings Classification · 95% confidence The document is a formal communication dated February 22, 2022, addressed to the 'Comisión Nacional del Mercado de Valores' (CNMV), the Spanish securities market regulator. It announces that Pharma Mar, S.A. will host a webinar for analysts and investors on March 9, 2022, featuring key opinion leaders discussing small cell lung cancer treatments. The document explicitly states it is providing 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information) as required by Spanish securities law (Article 227 of the Consolidated Text of the Securities Market Law). It also mentions that a press release is attached. Since this is an announcement of a future event (a webinar/investor presentation) and the release of supplementary material (press release), and it is being filed with the regulator, it fits best under the general category for regulatory announcements that aren't specific financial reports (like 10-K or IR) or direct management/board changes. Given the content is about an investor event and includes a press release, it is a general regulatory filing. While it relates to an Investor Presentation (IP), the primary nature of this filing is the regulatory disclosure itself. Therefore, 'Regulatory Filings' (RNS) is the most appropriate general classification for this type of mandatory disclosure of relevant, non-standard information.
2022-02-22 Spanish
Motivo de la notificación: Persona con Responsabilidad de Dirección
Director's Dealing Classification · 100% confidence The document is titled "MODELO DE NOTIFICACIÓN DE LAS OPERACIONES DE LAS PERSONAS CON RESPONSABILIDADES DE DIRECCIÓN Y DE LAS PERSONAS ESTRECHAMENTE VINCULADAS CON ELLAS" (Standard Form for Notification and Public Disclosure of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated with Them). This form explicitly details transactions (Compra/Buy) made by a Director (CONSEJERO (PRESIDENTE)) of the issuer (PHARMA MAR, S.A.). This directly corresponds to the definition of Director's Dealing, which covers reports of personal share transactions by company directors and executives (insider trades). The appropriate code is DIRS.
2022-01-25 Spanish
La Sociedad informa de la publicación del artículo de investigación “Pre-clinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19” en la revista científica Life Scie
Regulatory Filings Classification · 99% confidence The document is a formal communication addressed to the 'Comisión Nacional del Mercado de Valores' (CNMV, the Spanish securities market regulator) dated January 11, 2022. It is titled 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information) and announces the publication of a scientific article in the journal 'Life Science Alliance' regarding the drug plitidepsin and its activity against COVID-19 variants, including Omicron. It explicitly states, 'Se adjunta nota de prensa que será distribuida a los medios de comunicación en el día de hoy' (A press release that will be distributed to the media today is attached). The content is essentially a press release detailing clinical and preclinical study results. This structure—a brief regulatory notification announcing the release of detailed information (a press release/study results)—fits the definition of a Report Publication Announcement (RPA) or, if it's a general regulatory disclosure not fitting other specific categories, a Regulatory Filing (RNS). Since the core purpose is announcing the publication of results and attaching the press release, RPA is highly appropriate. It is not the full Annual Report (10-K), an Interim Report (IR), or a Call Transcript (CT). Given the context of a formal announcement to the regulator about published material, RPA is the best fit, although RNS is a close secondary option if RPA were unavailable or if the announcement itself was the primary focus rather than the publication event. Since RPA exists, it is preferred over the general RNS fallback.
2022-01-11 Spanish
La Sociedad remite detalle de las operaciones del Contrato de Liquidez comprendidas entre el 01/10/2021 y el 31/12/2021
Director's Dealing Classification · 95% confidence The document is a formal communication addressed to the 'Comisión Nacional del Mercado de Valores' (CNMV - Spanish Securities Market Commission) in Madrid, dated January 5, 2022. The subject is 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information) concerning 'Operaciones trimestrales contrato de liquidez' (Quarterly operations under a liquidity contract). It details the purchases and sales of shares executed under a liquidity agreement during the fourth quarter of 2021 (October 1 to December 31, 2021). This type of disclosure, which reports on insider/related party transactions or specific market stabilization activities (like liquidity contracts), falls under insider trading or director's dealing reports, or general regulatory disclosures. Given the specific nature of reporting transactions by directors/executives or related parties under a formal agreement, and comparing it against the provided definitions, it most closely aligns with reporting personal share transactions by company directors and executives (insider trades), which is covered by the 'Director's Dealing' code (DIRS). While it is a regulatory filing, DIRS is more specific than RNS. It is not an earnings release (ER), interim report (IR), or annual report (10-K). It is a specific report on share transactions, making DIRS the best fit.
2022-01-05 Spanish
La Sociedad anuncia la firma de un acuerdo de licencia y comercialización con Eczacibasi Pharmaceuticals Marketing Co. para comercializar el medicamento antitumoral lurbinectedina en Turquía.
Regulatory Filings Classification · 95% confidence The document is addressed to the 'Comisión Nacional del Mercado de Valores' (CNMV), the Spanish securities market regulator, and is dated December 22, 2021. It is explicitly titled 'OTRA INFORMACIÓN RELEVANTE' (Other Relevant Information) and announces a significant business event: a licensing and commercialization agreement for the anti-tumor drug lurbinectedin in Turkey. The text states, 'Se adjunta nota de prensa que será distribuida a los medios de comunicación en el día de hoy' (A press release that will be distributed to the media today is attached). This structure—a formal notification to the regulator accompanied by an attached press release detailing a material event—is characteristic of a general regulatory disclosure. Since the content is a specific business announcement (a licensing deal) rather than a standard periodic report (10-K, IR) or a specific corporate action vote (AGM-R, DVA), and it is being filed with the regulator as 'Other Relevant Information,' it fits best under the general regulatory filing category, RNS, which serves as a fallback for miscellaneous regulatory announcements not covered by more specific codes like ER or CAP. It is not a full Earnings Release (ER) or a Capital/Financing Update (CAP) in the sense of raising capital, but rather a commercial agreement.
2021-12-22 Spanish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.